Our study supports this approach by suggesting that patients with KIT mutations might be more likely to benefit from immunotherapy, although this did not reach statistical significance.
← all excerpts
Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
1
—
—